Status:
RECRUITING
IUS Combined With VAT Predicts Anti-TNF-α Efficacy in Patients With IBD: a Prospective Study
Lead Sponsor:
The Third Xiangya Hospital of Central South University
Conditions:
Inflammatory Bowel Diseases
Intestinal Ultrasound
Eligibility:
All Genders
18-80 years
Brief Summary
Inflammatory Bowel Disease (IBD) is a chronic recurrent nonspecific inflammatory disease of the intestinal tract that can involve multiple organs and systems, mainly including Crohn's disease (CD) and...
Detailed Description
Inflammatory Bowel Disease (IBD) is a chronic recurrent nonspecific inflammatory disease of the intestinal tract that can involve multiple organs and systems, mainly including Crohn's disease (CD) and...
Eligibility Criteria
Inclusion
- Age ≥ 18 years and ≤ 80 years;
- Patients with newly diagnosed or relapsed active IBD;
- Anti-TNF-α monotherapy is proposed to be applied within 1 month after baseline endoscopy;
- No history of abdominal surgery;
- Clearly understand, voluntarily participate in the study, and sign an informed consent form.
Exclusion
- Contraindications to anti-TNF-α therapy: allergy, active tuberculosis or other active infections, moderate-to-severe heart failure (NYHA grade III/IV), demyelinating lesions of the nervous system, live vaccination within the last 3 months, pregnancy and lactation;
- Patients with a history of extensive colectomy or recent proposed colectomy, history of colonic mucosal dysplasia;
- Hypersensitivity to the components of SonoVue contrast media.
Key Trial Info
Start Date :
November 22 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 30 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06165029
Start Date
November 22 2023
End Date
March 30 2025
Last Update
August 27 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
the Third Xiangya Hospital of Central South University
Changsha, Hunan, China, 410013